ArticleBrain and behavior2025
Longevity Code: Lipidome Associations and Mediated Metabolite Effects.
Article in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Longevity Code: Lipidome Associations and Mediated Metabolite Effects.Brain and behavior · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveThe effects of lipidome on longevity and the role of metabolites in between have not been fully elucidated. The purpose of this study was to assess the causal effects of lipidome on longevity and the mediated effects of metabolites using Mendelian randomization (MR).
methodsData on lipidome, metabolites, and longevity were acquired in the genome-wide association studies, and single-nucleotide polymorphisms meeting the basic assumptions of MR were selected. Subsequently, inverse variance weighted was employed as the primary method to analyze the causal effects of lipidome on longevity and the mediated effects of metabolites. Finally, MR-Egger intercept was used to assess horizontal pleiotropy in the results. Cochran's Q and leave-one-out sensitivity analysis were used to assess the heterogeneity and robustness of the results, respectively.
resultsThe MR analysis showed that sterol ester (27:1/18:3) decreased genetic susceptibility to longevity (90th) by reducing ethylenediaminetetraacetic acid (EDTA) levels (mediated proportion: 13.60%; mediated effect: -0.020, 95% confidence interval [CI] -0.039 to -0.002, p = 0.033); triacylglycerol (52:2) decreased genetic susceptibility to longevity (90th) by reducing EDTA levels (mediated proportion: 11.20%; mediated effect: -0.025, 95% CI -0.045 to -0.004, p = 0.020); triacylglycerol (54:5) decreased genetic susceptibility to longevity (90th) by increasing 1-arachidonoyl-gpc (20:4n6) levels (mediated proportion:8.37%; mediated effect: -0.010, 95% CI -0.021 to -9.44e-05, p = 0.048); phosphatidylcholine (O-16:0_18:2) increased genetic susceptibility to longevity (90th) by increasing EDTA levels (mediated proportion: 22.10%; mediated effect: 0.029, 95% CI 0.007-0.050, p = 0.008). MR-Egger intercept showed that these results lacked horizontal pleiotropy (p ≥ 0.05). Cochran's Q and sensitivity analysis showed that the MR results had no heterogeneity and were robust.
conclusionThe MR analysis revealed four pathways through which lipidome regulates longevity via metabolites. Lipidome such as sterol ester (27:1/18:3), phosphatidylcholine (O-16:0_18:2), triacylglycerol (52:2), and triacylglycerol (54:5), as well as metabolites such as EDTA and 1-arachidonoyl-gpc (20:4n6), may play important roles in longevity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.